Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL Biopharmaceuticals, a developer of therapeutics for the treatment of diabetic neuropathic pain and hepatitis C virus, has announced that the Bicifadine Phase IIb clinical trial for the treatment of diabetic neuropathic pain failed to meet its primary endpoint. The trial also failed to meet key secondary analysis.
Subscribe to our email newsletter
The trial’s primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in pain score during the course of the treatment.
Ron Bentsur, CEO of XTL Biopharmaceuticals, said: “We are all very disappointed with the results of the study. We will devote the next few days to further analyze the data and decide on the appropriate course of action for the Bicifadine program, and for the company.”